Skip to main content
Equibles
INO logo

INO · Inovio Pharmaceuticals, Inc. · Analyst Estimates

Track INO — free

Use INO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.30 +0.02 (+1.56%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Customer concentration — key customers 100% of revenue

Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)

“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
View the 10-K filed Mar 12, 2026
Market Cap
$132.35M
Shares
103.40M

Analyst Estimates

Compare analyst forecasts for Inovio Pharmaceuticals, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Only independently verified consensus published through the company's investor-relations sources is available.

Consensus not yet available

Only independently verified consensus published through the company's investor-relations sources is available.

Key facts CIK 1055726 CUSIP 45773H409 13F (30d) 61 filings 61 filers Visit website Investor relations